ASAH1

ASAH1 encodes lysosomal acid ceramidase, which hydrolyzes ceramide into sphingosine and free fatty acids and thereby maintains ceramide homeostasis across diverse cell types including podocytes, vascular smooth muscle cells, endothelial cells, and hepatocytes (PMID:32194052, PMID:32015399, PMID:39719015). The sphingosine product of ASAH1 activates the lysosomal TRPML1 Ca²⁺ channel, promoting lysosome–multivesicular body (MVB) fusion and directing MVB cargo to lysosomal degradation rather than exosome secretion; loss of ASAH1 therefore augments exosome release and, in specific contexts, drives arterial calcification via osteogenic extracellular vesicles or amplifies NLRP3 inflammasome signaling (PMID:33221496, PMID:32015399, PMID:31647995). Beyond its lysosomal catalytic role, ASAH1 localizes to the nucleus in adrenocortical cells, where it directly binds steroidogenic factor 1 (SF-1) on target gene promoters (CYP17A1, StAR) and represses SF-1-dependent transcription in a cAMP-regulated manner (PMID:22927646, PMID:19298866). Loss-of-function mutations in ASAH1 cause Farber lipogranulomatosis and the SMA-PME phenotypic spectrum, with disease-causing variants reducing ceramidase activity and disrupting precursor processing through splicing or missense defects (PMID:26945816, PMID:27026573, PMID:24355074).

1. 2009 High

   ASAH1 transcription was shown to be directly controlled by ACTH/cAMP–CREB signaling, establishing how the gene is induced in steroidogenic cells and linking its expression to hormonal regulation.

   Evidence ChIP, RNAi knockdown, reporter assays, and histone modification analysis in H295R adrenocortical cells

   PMID:19298866

   Open questions at the time

   • Whether CREB-dependent ASAH1 induction operates in non-adrenal tissues
   • Downstream consequences of ASAH1 induction on adrenal ceramide pools were not quantified
2. 2012 High

   Discovery that ASAH1 has a non-catalytic nuclear function—directly binding SF-1 on steroidogenic gene promoters and repressing transcription—revealed a dual lysosomal/nuclear role for the enzyme.

   Evidence Nuclear fractionation, reciprocal co-immunoprecipitation, ChIP, and RNAi in H295R cells

   PMID:22927646

   Open questions at the time

   • Whether the nuclear role requires catalytic activity or is purely scaffolding
   • Mechanism of ASAH1 nuclear import is unknown
   • Whether nuclear ASAH1 represses SF-1 targets in tissues other than adrenal cortex
3. 2013 Medium

   Characterization of splice-disrupting ASAH1 mutations defined the precursor cleavage requirement for enzyme activation, explaining how specific variants abolish function and cause Farber lipogranulomatosis.

   Evidence RT-PCR splice analysis and exonic splicing enhancer prediction/validation in patient-derived cells

   PMID:24355074

   Open questions at the time

   • No structural model of ASAH1 precursor cleavage site
   • Residual enzyme activity for each splice variant was not quantified
4. 2016 Medium

   Direct measurement of ceramidase activity in patient fibroblasts linked ASAH1 loss-of-function mutations to both Farber disease and the SMA-PME phenotypic spectrum, expanding the clinical impact of ASAH1 deficiency beyond lipogranulomatosis.

   Evidence Ceramidase enzyme activity assays and ceramide quantification in patient-derived fibroblasts, combined with exome/Sanger sequencing

   PMID:26945816 PMID:27026573

   Open questions at the time

   • The cell-type–specific basis for neuronal versus connective tissue manifestations of ASAH1 deficiency is unresolved
   • Rescue experiments with wild-type ASAH1 were not performed
5. 2018 Medium

   ASAH1 was positioned as a metabolic effector of melanoma phenotypic switching, with low ASAH1 promoting invasion via integrin αvβ5–FAK signaling, and as a protector against oxidative stress-induced ceramide accumulation in retinal cells.

   Evidence ASAH1 knockdown/overexpression with invasion assays and signaling pathway analysis in melanoma; lipidomic analysis under oxidative stress in ARPE19 cells

   PMID:30254208 PMID:30413652

   Open questions at the time

   • Whether ceramide species specificity determines ASAH1's pro-survival versus phenotype-switching roles
   • In vivo melanoma models were not used for validation
6. 2019 Medium

   Endothelium-specific ASAH1 deletion demonstrated that acid ceramidase deficiency redirects MVBs from lysosomal degradation to exosome secretion, amplifying NLRP3 inflammasome-derived IL-1β release, providing a mechanistic link between ceramide metabolism and vascular inflammation.

   Evidence Endothelium-specific conditional KO mouse model with NLRP3 inflammasome assays, exosome isolation, and confocal imaging of MVB–lysosome interaction

   PMID:31647995

   Open questions at the time

   • Direct measurement of TRPML1 activity in endothelial cells was not performed in this study
   • Whether inflammasome activation is ceramide-species specific is unresolved
7. 2020 High

   A convergent mechanism was established across podocytes and smooth muscle cells: ASAH1-derived sphingosine activates the lysosomal TRPML1 Ca²⁺ channel, which promotes lysosome–MVB fusion; loss of ASAH1 suppresses this axis, increasing exosome release and causing tissue-specific pathology (nephrotic syndrome in podocytes, arterial calcification in smooth muscle).

   Evidence Conditional KO mouse models (podocyte-specific and SMC-specific), lysosomal patch clamp (Port-a-Patch), GCaMP3 Ca²⁺ imaging, sphingosine rescue, genetic epistasis with Smpd1, sEV inhibitor (GW4869)

   PMID:32015399 PMID:32194052 PMID:33221496

   Open questions at the time

   • Whether sphingosine directly binds TRPML1 or acts through an intermediate
   • Structural basis for TRPML1 activation by sphingosine is unknown
   • Whether the sphingosine–TRPML1 axis operates in non-lysosomal compartments
8. 2024 Medium

   Hepatocyte-specific Asah1 deletion revealed that acid ceramidase is required for hepatic ceramide and cholesterol homeostasis, with its absence driving ER stress, impaired chaperone-mediated autophagy, lipid droplet biogenesis, and progression to steatohepatitis.

   Evidence Hepatocyte-specific conditional KO (Asah1fl/fl/Albcre), ceramide/cholesterol quantification, ER stress markers, autophagy assays, transcriptomic analysis

   PMID:39719015

   Open questions at the time

   • Mechanism linking ceramide accumulation to impaired chaperone-mediated autophagy is not fully delineated
   • Whether TRPML1 suppression underlies the hepatic phenotype was not tested
   • Therapeutic rescue with exogenous acid ceramidase was not attempted

• Key unresolved questions include the structural mechanism of ASAH1 precursor auto-cleavage and activation, whether sphingosine directly binds TRPML1, how ASAH1 is imported into the nucleus, and whether its catalytic and nuclear scaffolding functions are separable.
• No high-resolution structure of human ASAH1 in active or precursor form
• Separation-of-function mutants distinguishing catalytic versus nuclear roles have not been generated
• Direct biophysical evidence for sphingosine–TRPML1 binding is lacking